229 related articles for article (PubMed ID: 17410337)
21. A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.
Suemori K; Fujiwara H; Watanabe S; Azuma T; Yasukawa M
Int J Hematol; 2010 Dec; 92(5):777-8. PubMed ID: 21110146
[No Abstract] [Full Text] [Related]
22. Leukemia. Q&A highlights.
Frame D; Sessions J; Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S22. PubMed ID: 18056929
[No Abstract] [Full Text] [Related]
23. Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
Mabed M; Elhefni AM; Damnhouri G
Leuk Lymphoma; 2012 Nov; 53(11):2310-1. PubMed ID: 22462614
[No Abstract] [Full Text] [Related]
24. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
Raanani P; Goldman JM; Ben-Bassat I
J Clin Oncol; 2002 Feb; 20(3):869-70. PubMed ID: 11821474
[No Abstract] [Full Text] [Related]
25. Gleevec: tailoring to fit.
May TS
Drug Discov Today; 2003 Mar; 8(5):188-9. PubMed ID: 12634004
[No Abstract] [Full Text] [Related]
26. [Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML].
Shu LL; Jiang QL; Meng FY; Yang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1314-8. PubMed ID: 22040995
[TBL] [Abstract][Full Text] [Related]
27. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
28. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
Ikeda K; Shiga Y; Takahashi A; Kai T; Kimura H; Takeyama K; Noji H; Ogawa K; Nakamura A; Ohira H; Sato Y; Maruyama Y
Leuk Lymphoma; 2006 Jan; 47(1):155-7. PubMed ID: 16321842
[TBL] [Abstract][Full Text] [Related]
29. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
[No Abstract] [Full Text] [Related]
30. Bilateral masculine mastoplasia associated with imatinib mesylate: a case report and literature review.
Zhao D; Wang G; Li C; Meng L
J Huazhong Univ Sci Technolog Med Sci; 2011 Feb; 31(1):145-146. PubMed ID: 21336741
[No Abstract] [Full Text] [Related]
31. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
Martínez Pascual C; Valdés Mas M; de la Peña Moral JM; Miras López M
Med Clin (Barc); 2011 Sep; 137(7):329-30. PubMed ID: 21074222
[No Abstract] [Full Text] [Related]
32. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
Schoch C; Haferlach T; Kern W; Schnittger S; Berger U; Hehlmann R; Hiddemann W; Hochhaus A
Leukemia; 2003 Feb; 17(2):461-3. PubMed ID: 12592348
[No Abstract] [Full Text] [Related]
33. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.
Millot F; Baruchel A; Guilhot J; Petit A; Leblanc T; Bertrand Y; Mazingue F; Lutz P; Vérité C; Berthou C; Galambrun C; Bernard F; Yacouben K; Bordigoni P; Edan C; Reguerre Y; Couillault G; Méchinaud F; Cayuela JM; Guilhot F
J Clin Oncol; 2011 Jul; 29(20):2827-32. PubMed ID: 21670449
[TBL] [Abstract][Full Text] [Related]
34. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
[TBL] [Abstract][Full Text] [Related]
35. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
Lau YM; Lam YK; Leung KH; Lin SY
Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
[No Abstract] [Full Text] [Related]
36. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
37. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
Ramar K; Potti A; Mehdi SA
J Clin Oncol; 2003 Jan; 21(1):172-3. PubMed ID: 12506189
[No Abstract] [Full Text] [Related]
38. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
39. Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?
Fava C; Saglio G
Semin Hematol; 2010 Oct; 47(4):319-26. PubMed ID: 20875548
[TBL] [Abstract][Full Text] [Related]
40. Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.
Khoo TL; Catalano A; Supple S; Chong L; Yeoh SC; Yeung S; Iland H
Leuk Lymphoma; 2013 Jan; 54(1):186-8. PubMed ID: 22712835
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
